Both in vivo and in vitro experiments have demonstrated that the GLS1 inhibitor BPTES normalized the effector function of CD4+ T cells and effectively improved the dysregulation of exocrine glands in Sjogren’s syndrome (SS) (98). This evidence concerns the gene CD4 and synovial sarcoma.